Abstract
The meta-analysis aims to investigate association between two matrix metalloproteinases (MMPs) polymorphisms (MMP-2 −1306 C/T and MMP-9 −1562 C/T) and breast cancer risk. Eligible studies were retrieved from relevant databases, based on predefined criteria. Quality assessment was evaluated by Newcastle–Ottawa Scale. Odds ratio (OR) with its 95% confidence interval (CI) was selected as the effect size for the meta-analysis. As a result, 13 studies were included. MMP-2 −1306 C/T polymorphism was not significantly associated with breast cancer risk under all genetic models (P > 0.05). However, subgroup analysis stratified by ethnicity showed a significant association between MMP-2 −1306 C/T polymorphism and reduced breast cancer risk in Asian populations under allelic model (OR 0.60, 95% CI 0.39–0.90, P = 0.02) and dominant model (OR 0.55, 95% CI 0.34–0.89, P = 0.02). MMP-9 −1562 C/T polymorphism was significantly related to increased breast cancer risk under allelic model (OR 1.50, 95% CI 1.06–2.12, P = 0.02), additive model (OR 1.45, 95% CI 1.02–2.05, P = 0.04) and recessive model (OR 1.54, 95% CI 1.13–2.12, OR 0.007). A significant association between MMP-9 −1562 C/T polymorphism and increased breast cancer risk in Caucasian was detected under most of the genetic models (P < 0.05). MMP-2 −1306 C/T polymorphism might be significantly associated with reduced breast cancer risk in Asian, while MMP-9 −1562 C/T might be closely related to increased breast cancer risk, especially in Caucasian.
Similar content being viewed by others
References
Bauvois B (2012) New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. BBA-Rev Cancer 1825:29–36
Chia CY, Kumari U, Casey PJ (2014) Breast cancer cell invasion mediated by Gα12 signaling involves expression of interleukins-6 and -8, and matrix metalloproteinase-2. J Mol Signal 9:6
Chiranjeevi P, Spurthi KM, Rani NS, Kumar GR, Aiyengar TM, Saraswati M, Srilatha G, Kumar GK, Sinha S, Kumari CS (2014) Gelatinase B (−1562 C/T) polymorphism in tumor progression and invasion of breast cancer. Tumor Biol 35:1351–1356
Cuijpers P, Smit F, Bohlmeijer E, Hollon SD, Andersson G (2010) Efficacy of cognitive–behavioural therapy and other psychological treatments for adult depression: meta-analytic study of publication bias. Br J Psychiatry 196:173–178
Delgado-Enciso I, Cepeda-Lopez FR, Monrroy-Guizar EA, Bautista-Lam JR, Andrade-Soto M, Jonguitud-Olguin G, Rodriguez-Hernandez A, Anaya-Ventura A, Baltazar-Rodriguez LM, Orozco-Ruiz M (2008) Matrix metalloproteinase-2 promoter polymorphism is associated with breast cancer in a Mexican population. Gynecol Obstet Investig 65:68–72
DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J, Anderson BO, Jemal A (2015) International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomark Prev 24:1495–1506
El Samanoudy A, Monir R, Badawy A, Ibrahim L, Farag K, El Baz S, Alenizi D, Alenezy A (2014) Matrix metalloproteinase-9 gene polymorphism in hepatocellular carcinoma patients with hepatitis B and C viruses. Genet Mol Res 13:8025–8034
Feng R-N, Zhao C, Sun C-H, Li Y (2011) Meta-analysis of TNF 308 G/A polymorphism and type 2 diabetes mellitus. PLoS ONE 6:e18480
Grieu F, Li WQ, Iacopetta B (2004) Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype. Breast Cancer Res Treat 88:197–204
Holliday DL, Hughes S, Shaw JA, Walker RA, Jones JL (2007) Intrinsic genetic characteristics determine tumor-modifying capacity of fibroblasts: matrix metalloproteinase-3 5A/5A genotype enhances breast cancer cell invasion. Breast Cancer Res 9:R67
Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127:820–826
Lei H, Hemminki K, Altieri A, Johansson R, Enquist K, Hallmans G, Lenner P, Försti A (2007) Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression. Breast Cancer Res Treat 103:61–69
Nagase H, Visse R (2009) Matrix metalloproteinases: an overview. In: Supuran CT, Winum JY (eds) Drug design of zinc-enzyme inhibitors: functional, structural, and disease applications. Wiley, Hoboken, pp 487–517
Néjima DB, Zarkouna YB, Gammoudi A, Manai M, Boussen H (2015) Prognostic impact of polymorphism of matrix metalloproteinase-2 and metalloproteinase tissue inhibitor-2 promoters in breast cancer in Tunisia: case-control study. Tumor Biol 36:3815–3822
Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, O’Meara ES, Buist DS, Kerlikowske K, van Ravesteyn NT, Trentham-Dietz A (2012) Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med 156:635–648
Przybylowska K, Kluczna A, Zadrozny M, Krawczyk T, Kulig A, Rykala J, Kolacinska A, Morawiec Z, Drzewoski J, Blasiak J (2006) Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Breast Cancer Res Treat 95:65–72
Rahimi Z, Yari K (2015) Matrix metalloproteinase-9 −1562T allele and its combination with MMP-2 −735 C allele are risk factors for breast cancer. Asian Pac J Cancer Prev 16:1175–1179
Roehe AV, Frazzon APG, Agnes G, Damin AP, Hartman AA, Graudenz MS (2007) Detection of polymorphisms in the promoters of matrix metalloproteinases 2 and 9 genes in breast cancer in South Brazil: preliminary results. Breast Cancer Res Treat 102:123–124
Sadeghi M, Motovali-Bashi M, Hojati Z (2009) MMP-9 promoter polymorphism associated with tumor progression of breast cancer in Iranian population. Int J Integr Biol 6:33–37
Saeed HM, Alanazi MS, Alshahrani O, Parine NR, Alabdulkarim HA, Shalaby MA (2013) Matrix metalloproteinase-2 C-1306T promoter polymorphism and breast cancer risk in the Saudi population. Acta Biochim Pol 60:405–409
Salanti G, Amountza G, Ntzani EE, Ioannidis JP (2005) Hardy-Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur J Hum Genet 13:840–848
Schveigert D, Cicenas S, Bruzas S, Samalavicius N, Gudleviciene Z, Didziapetriene J (2013) The value of MMP-9 for breast and non-small cell lung cancer patients’ survival. Adv Med Sci 58:73–82
Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64:9–29
Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605
Turpeenniemi-Hujanen T (2005) Gelatinases (MMP-2 and-9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 87:287–297
Wang XW, Deng Y, Yang YL, Xu LS (2013) Association between polymorphisms of MMP-9, Bcl-2 and Chinese Han patients with breast cancer in Qinghai area. J Qinghai Med Coll 34:31–37
Wang XW, Su ZH, Yang YL, Xu T (2014) Polymorphisms of MMP-2 and MMP-9 and the susceptibility of breast cancer in the Hans of Qinghai. Matern Child Health Care China 29:1094–1097. doi:10.7620/zgfybj.j.issn.1001-4411.2014.07.42
Yang L, Li N, Wang S, Kong Y, Tang H, Xie X (2013) Lack of association between the matrix metalloproteinase-2 −1306 C > T polymorphism and breast cancer susceptibility: a meta-analysis. Asian Pac J Cancer Prev 15:4823–4827
Ye S (2000) Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol 19:623–629
Zagouri F, Sergentanis TN, Gazouli M, Dimitrakakis C, Tsigginou A, Papaspyrou I, Chrysikos D, Lymperi M, Zografos GC, Antsaklis A (2013) MMP-2 −1306 C > T polymorphism in breast cancer: a case–control study in a South European population. Mol Biol Rep 40:5035–5040
Zhang L-F, Mi Y-Y, Cao Q, Wang W, Qin C, Wei J-F, Zhou Y-J, Li Y-F, Tang M, Liu W-M (2012) Update analysis of studies on the MMP-9 −1562 C > T polymorphism and cancer risk. Mol Biol Rep 39:3435–3441
Zhang X, Jin G, Li J, Zhang L (2015) Association between four MMP-9 polymorphisms and breast cancer risk: a meta-analysis. Med Sci Monit 21:1115
Zhou Y, Yu C, Miao X, Tan W, Liang G, Xiong P, Sun T, Lin D (2004) Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis 25:399–404
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
Meng Han, Qingfeng Yang, Kai Feng, Rongping Li, Jia Ren, and Liguang Wei declares that they have no conflict of interest.
Ethical approval
In this study, no tissue or sample was obtained from human or animal. This study was compliant with ethical standards.
Rights and permissions
About this article
Cite this article
Han, M., Yang, Q., Feng, K. et al. Associations of MMP-2 −1306 C/T and MMP-9 −1562 C/T polymorphisms with breast cancer risk among different populations: a meta-analysis. Genes Genom 39, 331–340 (2017). https://doi.org/10.1007/s13258-016-0498-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13258-016-0498-z